Oxaflozane
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxaflozane (Conflictan) is an antidepressant and anxiolytic drug that was introduced in France in 1982 by Solvay for the treatment of depression, but has since been abandoned.[1][2] It is a prodrug to N-dealkyloxaflozane, which acts as a non-selective serotonin receptor agonist for the 5-HT1A (pKi = 7.1), 5-HT2A (pKi = 6.0), and 5-HT2C (pKi = 7.5) subtypes.[3] Oxaflozane may also have anticholinergic effects in high doses.[4]
References
- ↑ Swiss Pharmaceutical Society (2000). Index Nominum 2000: International Drug Directory (Book with CD-ROM). Boca Raton: Medpharm Scientific Publishers. p. 766. ISBN 3-88763-075-0.
- ↑ Sittig, Marshall (1988). Pharmaceutical manufacturing encyclopedia. Park Ridge, N.J., U.S.A: Noyes Publications. p. 1122. ISBN 0-8155-1144-2.
- ↑ Leysen DC (February 1999). “Selective 5-HT2C agonists as potential antidepressants”. IDrugs : the Investigational Drugs Journal. 2 (2): 109–20. PMID 16160946.
- ↑ Dutertre JP, Barbier P, Suc AL, Jonville AP, Autret E (1992). “Oxaflozane overdose in a child”. Journal of Toxicology. Clinical Toxicology. 30 (1): 123–6. doi:10.3109/15563659208994452. PMID 1542141.
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH